ProCE Banner Activity

ASH 2019 Preview: Key Studies in CAR T-Cell Therapy

Clinical Thought
In this commentary, Matthew J. Frigault, MD, highlights key studies of CAR T-cell therapy that will be presented at the upcoming 2019 ASH annual meeting in Orlando.

Released: December 04, 2019

Expiration: December 02, 2020

Share

Faculty

Matthew J. Frigault

Matthew J. Frigault, MD

Instructor of Medicine
Division of Oncology
Department of Internal Medicine
Harvard Medical School
Clinical Assistant
Hematopoietic Cell Transplant and Cellular Therapy Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Celgene

Kite A GILEAD Company

Faculty Disclosure

Primary Author

Matthew J. Frigault, MD

Instructor of Medicine
Division of Oncology
Department of Internal Medicine
Harvard Medical School
Clinical Assistant
Hematopoietic Cell Transplant and Cellular Therapy Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Matthew J. Frigault, MD, has disclosed that he has received consulting fees from Arcellx, Celgene, Foundation, Kite/Gilead Sciences, Nkarta, Novartis, and Xenetic.